David E. Strauss serves as Corporate Controller of the Company. Prior to joining the Company, Mr. Strauss served as Corporate Controller of Landec Corporation, a publicly-traded material science company, from March 2019 to January 2020. Previously, Mr. Strauss he served as Assistant Controller at Analog Devices, Inc. from March 2017 to February 2019. From March 2015 to February 2017, he served as External Reporting Manager for Linear Technology. Corp. Prior to that, Mr. Strauss spent four years in public accounting with PricewaterhouseCoopers LLP. Mr. Strauss received a B.S. in Business Administration from San Jose State University.
David Strauss is 34, he's been the Corporate Controller of Bellicum Pharmaceuticals Inc since 2020. There are 16 older and no younger executives at Bellicum Pharmaceuticals Inc. The oldest executive at Bellicum Pharmaceuticals Inc is Dr. Alan K. Smith Ph.D., 63, who is the Chief Scientific Officer.
David's mailing address filed with the SEC is C/O BELLICUM PHARMACEUTICALS, INC., 611 GATEWAY BLVD., SUITE 820, SOUTH SAN FRANCISCO, CA, 94080.
Over the last 10 years, insiders at Bellicum Pharmaceuticals Inc have traded over $18,000,835 worth of Bellicum Pharmaceuticals Inc stock and bought 249,666 units worth $2,145,232 . The most active insiders traders include Bros. Advisors Lp Baker Bro..., Bros. Advisors Lpbaker Feli... a Jon P Stonehouse. On average, Bellicum Pharmaceuticals Inc executives and independent directors trade stock every 32 days with the average trade being worth of $2,494. The most recent stock trade was executed by James M Daly on 3 January 2023, trading 60,414 units of BLCM stock currently worth $4,516.
bellicum pharmaceuticals, located near the houston medical center, is a clinical stage biopharmaceutical company focused on discovering and developing novel cellular immunotherapies for various forms of cancer, including both hematological and solid tumors, as well as orphan inherited blood disorders. we are developing next-generation product candidates in some of the most important areas of cellular immunotherapy, including hematopoietic stem cell transplantation (hsct) and car t cell therapy. we are dedicated to creating an exceptional work environment and are passionate about working to provide innovative new treatment options that can improve health and save lives.
Bellicum Pharmaceuticals Inc executives and other stock owners filed with the SEC include: